Envision Healthcare Corporation, through its subsidiaries, provides various healthcare services in the United States. The company operates through two segments, Physician Services and Ambulatory Services. As of December 31, 2017, its physician-led services encompassed providers at approximately 1,800 clinical departments at healthcare facilities in 45 states and the District of Columbia that include emergency department and hospitalist, anesthesiology, radiology/tele-radiology, and children's services. The company also offers ambulatory surgical centers (ASCs) services that provide surgical procedures across multiple specialties, including gastroenterology, ophthalmology, orthopedics, and others. It operated 264 ASCs in 35 states and the District of Columbia. In addition, it provides surgery services, such as management, oversight, and surgeon staffing for trauma surgery services; offers direct patient care and care coordination by clinicians outside the acute care setting through physician-led post-acute care services; and operates office-based medical practices that primarily focus on women's health, as well as provides physician staffing and related management services. Further, it offers medical transportation services in 41 states and the District of Columbia. The company offers its clinical solutions for health systems, payors, providers, and patients. Envision Healthcare Corporation was founded in 1992 and is based in Nashville, Tennessee.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Offices & clinics of medical doctors
Sub-IndustryN/A
SectorMedical
Current SymbolNYSE:EVHC
Previous Symbol
CUSIPN/A
Phone615-665-1283
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees69,300
Outstanding SharesN/A
Market Cap$0.00
OptionableOptionable
Envision Healthcare (NYSE:EVHC) Frequently Asked Questions
What is Envision Healthcare's stock symbol?
Envision Healthcare trades on the New York Stock Exchange (NYSE) under the ticker symbol "EVHC."
How will Envision Healthcare's stock buyback program work?
Envision Healthcare announced that its Board of Directors has initiated a share repurchase plan on Tuesday, September 19th 2017, which authorizes the company to buyback $250,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to reacquire up to 4.5% of its shares through open market purchases. Shares buyback plans are generally an indication that the company's leadership believes its stock is undervalued.
How were Envision Healthcare's earnings last quarter?
Envision Healthcare Corp (NYSE:EVHC) released its quarterly earnings results on Monday, August, 6th. The company reported $0.92 EPS for the quarter, beating the Zacks' consensus estimate of $0.87 by $0.05. The business earned $2.07 billion during the quarter, compared to the consensus estimate of $2.10 billion. Envision Healthcare's revenue was up 6.5% on a year-over-year basis. During the same quarter last year, the business earned $0.85 EPS. View Envision Healthcare's Earnings History.
What price target have analysts set for EVHC?
12 brokerages have issued 12 month price targets for Envision Healthcare's shares. Their predictions range from $34.00 to $51.00. On average, they anticipate Envision Healthcare's share price to reach $43.8636 in the next twelve months. This suggests that the stock has a possible downside of 4.6%. View Analyst Price Targets for Envision Healthcare.
What is the consensus analysts' recommendation for Envision Healthcare?
12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Envision Healthcare in the last year. There are currently 10 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Envision Healthcare.
What are Wall Street analysts saying about Envision Healthcare stock?
Here are some recent quotes from research analysts about Envision Healthcare stock:
- 1. According to Zacks Investment Research, "Envision Healthcare’s shares have outperformed the industry year to date. We are optimistic about the physician services market witnessing consolidation. Also, the divestiture of its AMR business will help the company focus on its core operations. The company’s strategic acquisitions that have led to inorganic growth have also been a driving force. However, the company suffers high leverage, leading to increased interest ratio. Its operating expense is exceeding revenue growth and exerting pressure on operating margins. " (9/7/2018)
- 2. Cantor Fitzgerald analysts commented, ". We are reiterating our Neutral rating, but adjusting our 2018 and 2019 estimates to reflect 2Q18 results, and raising our price target to $46 from $40, to reflect KKR’s pending acquisition of EVHC. The company’s progress towards cost cutting showed in 2Q18 as adjusted EBITDA was higher than our estimate, despite flat volumes and lower than expected revenue, on lower supply costs and other operating expenses. The $9.9 billion (including $4.4 billion of debt) deal is expected to close in 4Q18 and represents a multiple of 10x our 2018 adjusted EBITDA estimate." (8/10/2018)
- 3. Canaccord Genuity analysts commented, "We reiterate our BUY rating and raise our PT to $46 based on an improving financial outlook given restructuring and easing utilization headwinds. The company characterized guidance as highly visible and not heroic. As such, we recommend continued exposure as utilization headwinds dissipate and the operational improvement plan takes hold. Key positive: High visibility into 2018 guidance: The low-end of 2018 adj-EBITDA of $960M is 87% in hand when annualizing 4Q’17. M&A from 2017 and 2018 should contribute an incremental $10-$15M and $20-$30M, respectively, bringing visibility up to 92% coverage at the low-end. Organic growth and further expense benefits from operational improvements would be the last leg in getting to guidance. Key negative: Consolidated organic growth rate lowered to 2-5% (was 3-6%) taking into account a softer utilization environment." (2/28/2018)
Has Envision Healthcare been receiving favorable news coverage?
News articles about EVHC stock have been trending neutral on Sunday, InfoTrie Sentiment reports. The research firm scores the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Envision Healthcare earned a daily sentiment score of 0.2 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 9.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the near future.
Who are some of Envision Healthcare's key competitors?
Some companies that are related to Envision Healthcare include 22nd Century Group (XXII), 3D Signatures (DXD), 4d Pharma (DDDD), Abattis Bioceuticals (ATTBF), Abaxis (ABAX), Abcam (ABC), ABcann Global (ABCN), ABLYNX NV/ADR (ABLX), ABZENA/PAR VTG FPD 0.002 (ABZA), Acasti Pharma (ACST), Acerus Pharmaceuticals (ASP), Acrux (ACR), Actinium Pharmaceuticals (ATNM), Activecare (ACAR) and Advanced Accelerator Application (AAAP).
Who are Envision Healthcare's key executives?
Envision Healthcare's management team includes the folowing people:
- Mr. Christopher A. Holden, CEO, Pres & Director (Age 54)
- Ms. Claire M. Gulmi, Advisor (Age 64)
- Mr. Kevin D. Eastridge, Exec. VP & CFO (Age 53)
- Mr. Karey Lynn Witty, Exec. VP & COO (Age 53)
- Mr. Kenneth E Zongor, Sr. VP & Chief Accounting Officer (Age 42)
Who are Envision Healthcare's major shareholders?
Envision Healthcare's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (0.00%), Dimensional Fund Advisors LP (0.00%), JPMorgan Chase & Co. (0.00%), Man Group plc (0.00%), FMR LLC (0.00%) and Sandell Asset Management Corp. (0.00%). Company insiders that own Envision Healthcare stock include John Thomas Gawaluck and Robert Jon Coward. View Institutional Ownership Trends for Envision Healthcare.
Which major investors are selling Envision Healthcare stock?
EVHC stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, JPMorgan Chase & Co., Toronto Dominion Bank, Douglas Lane & Associates LLC, Credit Suisse AG, Alliancebernstein L.P., SG Americas Securities LLC and Broadview Advisors LLC. View Insider Buying and Selling for Envision Healthcare.
Which major investors are buying Envision Healthcare stock?
EVHC stock was bought by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Sandell Asset Management Corp., IndexIQ Advisors LLC, Hsbc Holdings PLC, FIL Ltd, City Financial Investment Co Ltd, BlackRock Inc. and Janus Henderson Group PLC. View Insider Buying and Selling for Envision Healthcare.
How do I buy shares of Envision Healthcare?
Shares of EVHC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Envision Healthcare's stock price today?
One share of EVHC stock can currently be purchased for approximately $45.99.
What is Envision Healthcare's official website?
How can I contact Envision Healthcare?
Envision Healthcare's mailing address is 1A BURTON HILLS BOULEVARD, NASHVILLE TN, 37215. The company can be reached via phone at 615-665-1283 or via email at [email protected]
MarketBeat Community Rating for Envision Healthcare (NYSE EVHC)
MarketBeat's community ratings are surveys of what our community members think about Envision Healthcare and other stocks. Vote "Outperform" if you believe EVHC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EVHC will underperform the S&P 500 over the long term. You may vote once every thirty days.
